Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis

Authors

  • Karn Wijarnpreecha Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
  • Elizabeth S Aby Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota, United States
  • Hassan Ghoz Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
  • Wisit Cheungpasitporn Department of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Frank J Lukens Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
  • Denise M Harnois Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States
  • Patompong Ungprasert Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, United States

DOI:

https://doi.org/10.15403/jgld-2990

Keywords:

statins, bile duct cancer, biliary tract cancer, cholangiocarcinoma, meta-analysis

Abstract

Background and Aims: The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.

Methods: A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.

Results: A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).

Conclusions: The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.

Downloads

Published

2020-12-13

How to Cite

1.
Wijarnpreecha K, Aby ES, Ghoz H, Cheungpasitporn W, Lukens FJ, Harnois DM, Ungprasert P. Statins and Risk of Cholangiocarcinoma: A Systematic Review and Meta-analysis. JGLD [Internet]. 2020 Dec. 13 [cited 2025 Jul. 14];29(4):629-35. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/2990

Issue

Vol. 29 No. 4: December 2020

Section

Systematic Review and Meta-Analysis